GLYXYN

Serial Number 90448135
734

Registration Progress

Application Filed
Jan 5, 2021
Under Examination
Oct 18, 2022
Approved for Publication
Feb 22, 2022
Published for Opposition
Feb 22, 2022
Registered

Attorney Assistance

Statement of Use Due - Extension 5 Granted
Due: Oct 18, 2025 79 days
Statement of Use required (all extensions used)

Trademark Image

GLYXYN

Basic Information

Serial Number
90448135
Filing Date
January 5, 2021
Published for Opposition
February 22, 2022
Drawing Code
4

Status Summary

Current Status
Active
Status Code
734
Status Date
Jul 7, 2025
Application
Pending
Classes
005

Rights Holder

Biohaven Therapeutics Ltd.

99
Address
Ritter House, P.O. Box 173
Road Town, Tortola VG1110
VG

Ownership History

Biohaven Therapeutics Ltd.

Original Applicant
99
New Haven, CT

Biohaven Therapeutics Ltd.

Owner at Publication
99
Road Town, Tortola VG

Legal Representation

Attorney
Monica Riva Talley

USPTO Deadlines

Next Deadline
79 days remaining
Statement of Use Due - Extension 5 Granted
Due Date
October 18, 2025

Application History

44 events
Date Code Type Description Documents
Jul 7, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 7, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jul 7, 2025 EX5G S SOU EXTENSION 5 GRANTED Loading...
Mar 10, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 9, 2025 EXT5 S SOU EXTENSION 5 FILED Loading...
Jul 24, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 23, 2024 EXT4 S SOU EXTENSION 4 FILED Loading...
Jul 23, 2024 EX4G S SOU EXTENSION 4 GRANTED Loading...
Jul 23, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 1, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 27, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 25, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jan 25, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Jan 25, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 14, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 12, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Sep 12, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 12, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Apr 17, 2023 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Apr 17, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Apr 17, 2023 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Apr 7, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 5, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Apr 5, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Apr 5, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 18, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 8, 2022 CHPB I POST PUBLICATION AMENDMENT - ENTERED Loading...
Sep 8, 2022 APET A ASSIGNED TO PETITION STAFF Loading...
Sep 1, 2022 ETOP T EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED Loading...
Aug 22, 2022 EPPA I TEAS POST PUBLICATION AMENDMENT RECEIVED Loading...
Mar 22, 2022 ETOF T EXTENSION OF TIME TO OPPOSE RECEIVED Loading...
Feb 22, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 22, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 2, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 19, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 18, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 18, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 18, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 16, 2021 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 16, 2021 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 16, 2021 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 14, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 3, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 8, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, Obsessive Compulsive Disorder (OCD); pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia; none of the aforementioned to include dietary and nutritional supplements or preparations for the treatment of diabetes or related conditions

Classification

International Classes
005